T细胞淋巴瘤的理解与管理方面的最新进展
Recent advances in understanding and managing T-cell lymphoma.
作者信息
Yi Jun Ho, Kim Seok Jin, Kim Won Seog
机构信息
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University , Seoul, Korea, South.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, Korea, South.
出版信息
F1000Res. 2017 Dec 12;6:2123. doi: 10.12688/f1000research.12573.1. eCollection 2017.
Abstract
Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.
摘要
由于外周T细胞淋巴瘤（PTCL）罕见且亚型具有异质性，目前尚无有力数据可指导此类患者的治疗方法。多年来，PTCL的分子分型和治疗取得了显著进展，尽管仍有许多领域有待探索。在本综述中，我们总结了PTCL在认识和治疗进展方面的最新情况。
相似文献
1
Recent advances in understanding and managing T-cell lymphoma.T细胞淋巴瘤的理解与管理方面的最新进展
F1000Res. 2017 Dec 12;6:2123. doi: 10.12688/f1000research.12573.1. eCollection 2017.
2
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.罗米地辛用于治疗外周T细胞淋巴瘤。
Oncologist. 2015 Sep;20(9):1084-91. doi: 10.1634/theoncologist.2015-0043. Epub 2015 Jun 22.
3
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.外周 T 细胞淋巴瘤中的造血细胞移植和过继细胞治疗。
Curr Hematol Malig Rep. 2020 Aug;15(4):316-332. doi: 10.1007/s11899-020-00590-5.
4
Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.侵袭性 T 细胞淋巴瘤：2024 年：诊断、风险分层和治疗的更新。
Am J Hematol. 2024 Mar;99(3):439-456. doi: 10.1002/ajh.27165. Epub 2024 Feb 2.
5
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.国际外周T细胞和自然杀伤/T细胞淋巴瘤研究：病理结果与临床结局
J Clin Oncol. 2008 Sep 1;26(25):4124-30. doi: 10.1200/JCO.2008.16.4558. Epub 2008 Jul 14.
6
Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.侵袭性 T 细胞淋巴瘤：2019 年诊断、风险分层和治疗的更新。
Am J Hematol. 2019 Aug;94(8):929-946. doi: 10.1002/ajh.25513. Epub 2019 Jun 11.
7
Peripheral T-cell lymphoma: are all patients high risk?外周T细胞淋巴瘤：所有患者都是高危吗？
Blood. 2024 Dec 19;144(25):2604-2612. doi: 10.1182/blood.2023020912.
8
Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.侵袭性 T 细胞淋巴瘤：2021 年诊断、风险分层和治疗的更新。
Am J Hematol. 2021 Aug 1;96(8):1027-1046. doi: 10.1002/ajh.26270. Epub 2021 Jun 26.
9
T cell and NK cell lymphoproliferative disorders.T细胞和NK细胞淋巴增殖性疾病。
Hematology Am Soc Hematol Educ Program. 2001:259-81. doi: 10.1182/asheducation-2001.1.259.
10
Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.外周T细胞淋巴瘤的基因组学及其对个性化医疗的意义。
Front Oncol. 2020 Jun 19;10:898. doi: 10.3389/fonc.2020.00898. eCollection 2020.
引用本文的文献
1
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.培拉曲塞治疗复发性或难治性外周 T 细胞淋巴瘤患者的多中心回顾性分析。
Sci Rep. 2019 Dec 30;9(1):20302. doi: 10.1038/s41598-019-56891-0.
2
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.培拉曲塞治疗复发或难治性外周 T 细胞淋巴瘤中国患者的单臂、多中心研究。
Target Oncol. 2019 Apr;14(2):149-158. doi: 10.1007/s11523-019-00630-y.
本文引用的文献
1
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.一项评估罗米地辛联合吉西他滨、地塞米松和顺铂方案治疗外周 T 细胞淋巴瘤和弥漫大 B 细胞淋巴瘤的 I 期临床研究：加拿大癌症临床试验组 LY.15 研究†。
Leuk Lymphoma. 2019 Apr;60(4):912-919. doi: 10.1080/10428194.2018.1515937. Epub 2018 Oct 10.
2
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.普拉曲沙用于日本复发或难治性外周T细胞淋巴瘤患者的I/II期研究。
Cancer Sci. 2017 Oct;108(10):2061-2068. doi: 10.1111/cas.13340. Epub 2017 Sep 4.
3
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.罗米地辛用于日本复发或难治性外周T细胞淋巴瘤患者：一项I/II期及药代动力学研究。
Int J Hematol. 2017 Nov;106(5):655-665. doi: 10.1007/s12185-017-2286-1. Epub 2017 Jun 29.
4
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.一项评估新型 PI3K 抑制剂 copanlisib 在复发/难治性惰性或侵袭性淋巴瘤患者中的疗效和安全性的 II 期临床研究。
Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.
5
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.吉西他滨、顺铂、泼尼松、沙利度胺与CHOP方案治疗新诊断外周T细胞淋巴瘤患者的疗效及安全性，并进行生物标志物分析
Br J Haematol. 2017 Sep;178(5):772-780. doi: 10.1111/bjh.14763. Epub 2017 Jun 9.
6
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.西达本胺治疗复发或难治性外周T细胞淋巴瘤：一项中国多中心真实世界研究
J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6.
7
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.帕博利珠单抗的 PD1 阻断在 l-天冬酰胺酶治疗失败的复发或难治性 NK/T 细胞淋巴瘤中具有高度疗效。
Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.
8
Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.II 型肠病相关 T 细胞淋巴瘤具有独特的基因组特征，高度重现 SETD2 改变。
Nat Commun. 2016 Sep 7;7:12602. doi: 10.1038/ncomms12602.
9
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.NCCN 指南解读：非霍奇金淋巴瘤，第 3.2016 版。
J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79. doi: 10.6004/jnccn.2016.0117.
10
Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety.帕博利珠单抗用于异基因造血干细胞移植后复发的间变性大细胞淋巴瘤：疗效与安全性。
Ann Hematol. 2016 Oct;95(11):1913-5. doi: 10.1007/s00277-016-2764-1. Epub 2016 Jul 30.
Zotero 插件